Fintel reports that James Wolf has filed a 13D/A form with the SEC disclosing ownership of 4,942,400 shares of Enzo Biochem, Inc. (ENZ). This represents 10.14% of the company.
In is previous filing dated November 23, 2022 Wolf reported 4,168,500 shares and 8.56% of the company, an increase in shares of 18.57% and an increase in total ownership of 1.58% (calculated as current – previous percent ownership
Wolf said in the filing he may nominate himself for election as a director of the Company at the next annual meeting of shareholders if he is not nominated or approved by the Board of Directors.
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
What are large shareholders doing?
Harbert Fund Advisors, Inc. holds 5,175,913 shares representing 10.62% ownership of the company. No change in the last quarter.
Renaissance Technologies Llc holds 2,909,664 shares representing 5.97% ownership of the company. In it’s prior filing, the firm reported owning 3,016,164 shares, representing a decrease of 3.66%. The firm increased its portfolio allocation in ENZ by 24.21% over the last quarter.
Roumell Asset Management, LLC holds 2,390,211 shares representing 4.91% ownership of the company. No change in the last quarter.
VIEX Capital Advisors, LLC holds 1,334,479 shares representing 2.74% ownership of the company. In it’s prior filing, the firm reported owning 1,536,857 shares, representing a decrease of 15.17%. The firm increased its portfolio allocation in ENZ by 14.45% over the last quarter.
Fuller & Thaler Asset Management, Inc. holds 971,010 shares representing 1.99% ownership of the company. In it’s prior filing, the firm reported owning 957,485 shares, representing an increase of 1.39%. The firm increased its portfolio allocation in ENZ by 14.23% over the last quarter.
Fund Sentiment
There are 91 funds or institutions reporting positions in Enzo Biochem, Inc.. This is a decrease of 12 owner(s) or 11.65%.
Average portfolio weight of all funds dedicated to Enzo Biochem, Inc. is 0.3169%, an increase of 20.3050%. Total shares owned by institutions decreased in the last three months by 3.34% to 23,764,544 shares.
This article originally appeared on Fintel
In 20 Years, I Haven’t Seen A Cash Back Card This Good
After two decades of reviewing financial products I haven’t seen anything like this. Credit card companies are at war, handing out free rewards and benefits to win the best customers.
A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges.
Our top pick today pays up to 5% cash back, a $200 bonus on top, and $0 annual fee. Click here to apply before they stop offering rewards this generous.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.